Skip to main content
. 2019 Apr 30;23(1):118–125. doi: 10.1007/s10120-019-00966-4

Table 2.

Reasons for no adjuvant therapy

Reasons for no adjuvant therapy Total N = 102 (%)
Fear of adverse events of imatinib 39 (38.2%)
Economic reasons 26 (25.5%)
Advanced age 20 (19.6%)
Patient refusal unknown 20 (19.6%)
Comorbidities 15 (14.7%)
Doubts for evidences of OS 10 (9.8%)
Re-review results of central pathology 3 (2.9%)
Fear of resistant mutations 2 (2.0%)
Poor PS 1 (1.0%)
Others 2 (2.0%)